Biodistribution and toxicity assessment of intratumorally injected arginine–glycine–aspartic acid peptide conjugated to CdSe/ZnS quantum dots in mice bearing pancreatic neoplasm

Li, Mingming; Cao, Jia; Yang, Jiachun; Shen, Yujie; Cai, Xiaolei; Chen, Yuanwen; Qu, Chun-Ying; Zhang, Yi; Shen, Feng; Zhou, Min; Xu, Leiming

doi:10.1016/j.cbi.2018.06.014

Cited by 14 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, research in the field of nano-toxicology requires greater attention. There are still some fields such as long-term toxicity studies that have not been performed as of yet (for example, kidney nanoparticle buildup), and obviously, improvements will be made regarding “Theranostic nano-medicine” by expanding novel versatile nanoparticles linking the skills of detection and the potential of therapy of pancreatic cancer, together with checking the medication delivery and its dispensation [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…Histopathologic examination of the major organs such as the liver or the kidney showed minimal toxicity. The experiment proved that RGD-conjugated QDs are good candidates for imaging and therapeutic applications, possessing various additional advantages such as low cost, easy preparation and low toxicity [ 35 ].…”

Section: Arginine–glycine–aspartic Acid Peptidementioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

Nedelcu

Mocan

Grapa

et al. 2021

IJMS

View full text Add to dashboard Cite

Pancreatic cancer (PC), one of the most lethal solid tumors in humans, has a five-year survival rate of only 4%. Surgical treatment is the only accepted therapy with curative intent because the vast majority of these tumors are chemoresistant. Unfortunately, due to the aggressive nature of these tumors, fewer than 20% are resectable when the first symptoms occur. Novel therapies are required to overcome all these therapeutic issues, and the development of active nanocarriers represents an exciting opportunity to improve PC outcomes. The present review focuses on recent advances in the field of nanotechnology with application in PC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Arginine–glycine–aspartic Acid Peptidementioning

confidence: 99%

Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

Nedelcu

Mocan

Grapa

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…59 Some studies have investigated amino acid metabolites in PC. [60][61][62] In our study, glycine was discovered to be metabolically different in the PC and splenic injection liver metastasis models. In recent years, many studies have shown that glycine and its related metabolites and enzymes are closely related to cancer.…”

Section: Discussionmentioning

confidence: 99%

Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD₈₂ Cell Line

Wang

Jiang

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Pancreatic cancer (PC) has a poor prognosis and is prone to liver metastasis. The KAI1/CD82 gene inhibits PC metastasis. This study aimed to explore differential metabolites and enrich the pathways in serum samples between PC and liver metastasis nude mouse models stably expressing KAI1/CD82. Methods: KAI1/CD82-PLV-EF1α-MCS-IRES-Puro vector and PANC1 cell line stably expressing KAI1/CD82 were constructed for the first time. This cell line was used to construct 3 PC nude mouse models and 3 liver metastasis nude mouse models. The different metabolites and Kyoto encyclopedia of genes and genomes (KEGG) and human metabolome database (HMDB) enrichment pathways were analyzed using the serum samples of the 2 groups of nude mouse models on the basis of untargeted ultra-performance liquid chromatography-tandem mass spectrometry platform. Results: KAI1/CD82-PLV-EF1α-MCS-IRES-Puro vector and PANC1 cell line stably expressing KAI1/CD82 were constructed successfully, and all nude mouse models survived and developed cancers. Among the 1233 metabolites detected, 18 metabolites (9 upregulated and 9 downregulated) showed differences. In agreement with the literature data, the most significant differences between both groups were found in the levels of bile acids (taurocholic acid, chenodeoxycholic acid), glycine, prostaglandin E2, vitamin D, guanosine monophosphate, and inosine. Bile recreation, primary bile acid biosynthesis, and purine metabolism KEGG pathways and a series of HMDB pathways ( P < .05) contained differential metabolites that may be associated with liver metastasis from PC. However, the importance of these metabolites on PC liver metastases remains to be elucidated. Conclusions: Our findings suggested that the metabolomic approach may be a useful method to detect potential biomarkers in PC.

show abstract

A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges

Kermanizadeh

Jacobsen

Murphy

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The design and utilization of nanomedicines offers great potential for treating various diseases including cancers. Current challenges with traditional cancer treatment strategies include but are not limited to lack of specific targeting, overt systemic toxicity and low efficacy. The use of nanomaterials show particular promise as candidates for cancer treatment due to their high surface to volume ratio and tuneable size, shape, and surface chemistry, which in combination, allow for improved tumor targeting and enhanced therapeutic efficacy. The scrutinization of the literature demonstrates the potential of nanosized carrier systems over traditional approaches (at the molecular level) for specific targeting of the tumors. Despite the great promise showing in preclinical studies, the number of nanomedicines reaching clinical testing is still very low. This review attempts to address this issue by using a weight of evidence approach to the different strategies for use of nanomedicines in combating cancer, as well as highlighting a number of areas that the field of nanomedicines is clearly lagging behind in, as compared to conventional drug discovery and development. It is hoped that the recommendations in this review will allow for better translation of nanomedicines reaching clinical trials.

show abstract

Biodistribution and toxicity assessment of intratumorally injected arginine–glycine–aspartic acid peptide conjugated to CdSe/ZnS quantum dots in mice bearing pancreatic neoplasm

Cited by 14 publications

References 42 publications

Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD₈₂ Cell Line

A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges

Contact Info

Product

Resources

About

Biodistribution and toxicity assessment of intratumorally injected arginine–glycine–aspartic acid peptide conjugated to CdSe/ZnS quantum dots in mice bearing pancreatic neoplasm

Cited by 14 publications

References 42 publications

Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD82 Cell Line

A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges

Contact Info

Product

Resources

About

Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD₈₂ Cell Line